SAB Biotherapeutics, Inc.

SABSSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1833214

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$1.3M	$2.2M	$23.9M	$60.9M	$55.2M
Research and Development Expense	$30.3M	$16.5M	$36.4M	$57.2M	$27.9M
Operating Expenses	$44.2M	$40.3M	$52.8M	$74.3M	$34.7M
Operating Income (Loss)	-$42.9M	-$38.1M	-$28.9M	-$13.4M	$20.6M
Interest Expense	—	—	$301.6K	$294.5K	$469.2K
Nonoperating Income (Expense)	$8.8M	-$4.1M	$10.2M	-$3.8M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$13.3M	—	-$18.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$44.2M	$83.9M	$50.9M	$81.1M	$56.5M
Assets, Current	$23.8M	$58.9M	$22.1M	$50.2M	$34.5M
Cash and Cash Equivalents, at Carrying Value	$8.9M	$56.6M	$15.0M	$33.2M	$12.6M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$5.6M	$8.0M	—
Liabilities	$18.2M	$26.6M	$19.8M	$42.6M	$17.5M
Liabilities, Current	$8.0M	$10.8M	$15.0M	$26.5M	$11.1M
Accounts Payable, Current	$1.7M	$945.9K	$3.7M	$4.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$34.3M	-$25.1M	-$23.5M	$2.0M	$10.0M
Net Cash Provided by (Used in) Investing Activities	-$12.0M	-$152.7K	-$2.1M	-$10.9M	-$12.7M
Net Cash Provided by (Used in) Financing Activities	-$1.2M	$66.8M	$1.1M	$35.9M	$9.0M
Payments to Acquire Property, Plant, and Equipment	$337.3K	$197.2K	$2.2M	$10.9M	$12.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)